Top Healthcare, Pharmaceutical and Biotechnology Focused Hedge Funds Revealed: Oversee nearly $28.7 Billion in Equity Assets

May 7th, 2013
| More
The Top 40 Healthcare, Pharmaceutical and Biotechnology Focused Hedge Fund list has been released, revealing that the top hedge funds now manage $28.7 billion in U.S. equity assets. The top 40 hedge funds allocate $19.7 billion, or 69% of their total equity assets, to Healthcare, Pharma & Biotech stocks.

The Top Healthcare, Pharma & Biotech Hedge Fund List is led by Samuel Isaly‘s OrbiMed Advisors and Larry Robbins’ Glenview Capital Management. While Isaly‘s OrbiMed Advisors is purely a healthcare focused investor, Robbins’ Glenview Capital is a global long/short equity investor that opportunistically makes big sector bets.

Some other notable hedge funds at the top of the hedge fund list include #6 Palo Alto Investors and #8 QVT Financial. William Edwards’ growth focused Palo Alto Investors reported U.S. equity assets of $854 million, dedicating 99.6% of its assets to Healthcare, Pharma & Biotech equities. The California-based firm focuses on healthcare and biotech stocks, typically concentrating its portfolio on 30 to 40 top stocks.

Daniel Gold’s QVT Financial, which employs convertible arbitrage, investment grade, and capital structure arbitrage techniques as well as various relative value-driven equity strategies, reported holdings of $999 in US equities, allocating 56% of those assets to Healthcare, Pharma & Biotech companies. Mr. Gold formed QVT in 1992 as a proprietary trading group within Deutsche Bank AG. The firm became independent in 2003 when Gold led its spin-off from Deutsche, beating out the Volcker Rule by more than half a decade.

Ranking Methodology: The Top Healthcare, Pharmaceutical and Biotechnology Hedge Fund rankings are compiled on a quarterly basis using hedge fund firms’ overall U.S. equity assets under management. The list includes the top hedge funds that have more than 35% of their U.S. equity assets invested in U.S. listed Healthcare, Pharma & Biotech companies, as of 12/31/2012. To view the Top Healthcare, Pharma & Biotech Hedge Fund list in its entirety, please visit HedgeTracker’s Hedge Fund Portal.
For Detailed Investor Profiles on these Investors, click below:
Glenview Capital Management
OrbiMed Advisors
Palo Alto Investors
QVT Financial
Related People: Corey Kosak; Daniel Gold; Dr. Anthony Yun; Julian Sale; Larry Robbins; Lars E. Bader; Samuel Isaly; Tracy Fu; William Edwards; Yi Cen
Related Entities: Caduceus Asia Partners LP; Caduceus Capital LP; Deutsche Bank; Eaton Vance Worldwide Health Sciences; Finsbury Worldwide Pharmaceutical; GCM Little Arbor Institutional Partners; GCM Little Arbor Master; GCM Little Arbor Partners; Glenview Capital Master; Glenview Capital Partners; Glenview Institutional Partners; OrbiMed Associates; OrbiMed Capital; Palo Alto Global Energy Fund LP; Palo Alto Healthcare Fund LP; Palo Alto Small Cap Fund LP; Palo Alto Technology Fund; QVT Financial LP; QVT Fund; QVT Hedge Fund; QVT Overseas
Related Article Tags: Multi-Strategy, Long Short, Equity, Debt and Global Macro Hedge Fund News; Featured Reports


More Recent Headlines

Tim Hortons’ Investors Skeptical of Highfields Capital’s Activist Proposals

Top Tech, Media & Telecom Hedge Funds prefer Apple, Equinix, Pandora Media & Shutterfly

Timothy Attias & Santiago Alarco's Canosa Capital launches with $300M

AIFMD – What you should be doing to comply

SAC Capital veteran Yip Ka-hay set to Launch Macro focused Bright Stream Capital Management

Largest Commodities Focused Hedge Funds Surpass $41 Billion in Assets

Icahn Capital veteran Alex Denner launching Health Care focused Activist hedge fund Sarissa Capital

Daniel Loeb’s Third Point to parlay Greek Debt Gains into New Hedge Fund Targeting Greek Assets

Microsoft Shares Get a Lift from Jeffrey Ubben’s ValueAct Capital

Jana Partners LLC’s investments ready to bloom after Sales of Business Units